Garuda - Garba Rujukan Digital

Case Report: 18 Year Old Male Patient with Lupus Nephritis Halim, Kurnia
International Journal of Public Health Excellence (IJPHE) Vol. 3 No. 2 (2024): January-May
Publisher : PT Inovasi Pratama Internasional

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55299/ijphe.v3i2.779

Systemic lupus erythematosus is a chronic autoimmune disease that can affect various organs of the body, one of the most commonly affected complications is the kidneys and results in lupus nephritis, the percentage of disease occurrence is more than 50% of patients in the first 5 years. Male patients tend to have more aggressive disease with renal, vascular, and cardiac involvement. Based on the criteria of Systemic Lupus International Collaborating Clinics in 2012 defines lupus nephritis if there is proteinuria in 24 hours ≥ 0.5 g / day, there is urine sediment, and there is a decrease in renal filtration function. Although the disease can be diagnosed based on these three things kidney biopsy remains the gold standard of diagnosis. In this case report, an 18-year-old male with lupus history came to the emergency room with the main complaint of fever accompanied by shortness of breath, from the results of supporting examinations obtained anemia, thrombocytopenia, high creatinine, and eGFR of 4 mL/minute, complete urine showed proteinuria, cylinders, and erythrocytes, AP thorax photos showed cardiomegaly, bronchopneumonia, and bilateral pleural effusions. Based on history, physical examination, lab, and imaging, the patient was diagnosed with systemic lupus erythematosus, lupus nephritis, chronic kidney disease, normocytic normochromic anemia, and community acquired pneumonia. The patient received glucocorticoids, immunosuppressants, diuretic, antihypertensives, antibiotics, and other supportive therapy, The patient also received renal replacement therapy in the form of hemodialysis and a kidney biopsy will be done after the condition improves

Vaccine-Based Immunotherapy for Metastatic Colorectal Cancer: A Systematic Review Amelia, Sesa; Mathlubaa, Asya; Amly, Harzalina Zilfi; Jacobs, Christin Yosefin; Halim, Kurnia; Heriawan, Timotius Ivan; Guantoro, Vincent; Putri, Hesti Andika
Medicinus Vol. 14 No. 3 (2025): June
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v14i3.10166

Background: Metastatic colorectal cancer (mCRC) remains a therapeutic challenge, particularly in microsatellite stable (MSS) tumors, which are largely unresponsive to current immunotherapy approaches. Vaccine-based immunotherapy offers a strategy to elicit tumor-specific immune responses in these immunologically “cold” tumors. However, clinical results have been mixed, and the efficacy and safety of cancer vaccines in mCRC remain to be clarified. Methods: A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines. Randomized controlled trials (RCTs) evaluating vaccine-based immunotherapy in mCRC were identified from PubMed, EMBASE, and Scopus as of May 2, 2025. Eligible studies included human subjects with mCRC receiving vaccine therapy with or without additional treatments, compared to standard or placebo regimens. The primary outcomes were overall survival (OS) and progression-free survival (PFS); safety was assessed by the incidence of grade ≥3 treatment-related adverse events. Result: Five RCTs comprising 804 patients met inclusion criteria. Pooled analysis showed a trend toward improved OS with vaccine-based immunotherapy (HR 0.81; 95% CI, 0.65–1.00; p = 0.05; I² = 0%), and a modest, non-significant improvement in PFS (HR 0.80; 95% CI, 0.62–1.05; p = 0.07; I² = 0%). The incidence of severe adverse events was lower with vaccine-based therapies (RR 0.31; 95% CI, 0.02–6.09; p = 0.23; I² = 90%). Conclusions: Vaccine-based immunotherapy in mCRC demonstrates potential clinical benefit, particularly in prolonging survival with a favorable safety profile. Further biomarker-driven studies are needed to optimize patient selection and therapeutic combinations.

Case Report: 18 Year Old Male Patient with Lupus Nephritis Halim, Kurnia
International Journal of Public Health Excellence (IJPHE) Vol. 3 No. 2 (2024): January-May
Publisher : PT Inovasi Pratama Internasional

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55299/ijphe.v3i2.779

Systemic lupus erythematosus is a chronic autoimmune disease that can affect various organs of the body, one of the most commonly affected complications is the kidneys and results in lupus nephritis, the percentage of disease occurrence is more than 50% of patients in the first 5 years. Male patients tend to have more aggressive disease with renal, vascular, and cardiac involvement. Based on the criteria of Systemic Lupus International Collaborating Clinics in 2012 defines lupus nephritis if there is proteinuria in 24 hours ≥ 0.5 g / day, there is urine sediment, and there is a decrease in renal filtration function. Although the disease can be diagnosed based on these three things kidney biopsy remains the gold standard of diagnosis. In this case report, an 18-year-old male with lupus history came to the emergency room with the main complaint of fever accompanied by shortness of breath, from the results of supporting examinations obtained anemia, thrombocytopenia, high creatinine, and eGFR of 4 mL/minute, complete urine showed proteinuria, cylinders, and erythrocytes, AP thorax photos showed cardiomegaly, bronchopneumonia, and bilateral pleural effusions. Based on history, physical examination, lab, and imaging, the patient was diagnosed with systemic lupus erythematosus, lupus nephritis, chronic kidney disease, normocytic normochromic anemia, and community acquired pneumonia. The patient received glucocorticoids, immunosuppressants, diuretic, antihypertensives, antibiotics, and other supportive therapy, The patient also received renal replacement therapy in the form of hemodialysis and a kidney biopsy will be done after the condition improves

Efficacy and Safety of Curcuma Longa Extract in Patients with Osteoarthritis: A Literature Review Halim, Kurnia; Gaol, Christine Lumban; Vira, Patricya; Utomo, Winno Pradana; Mahendika, Devin
Indonesian Journal of Global Health Research Vol 6 No 4 (2024): Indonesian Journal of Global Health Research
Publisher : GLOBAL HEALTH SCIENCE GROUP

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37287/ijghr.v6i4.2767

Osteoarthritis (OA) is a chronic degenerative inflammatory disease that attacks the joints, especially the knee joints, in millions of people throughout the world. The main symptom of this disease is joint pain. Many studies have shown that components of Curcuma longa have beneficial effects in the pain management of OA patients. Objective to determine the efficacy and side effects of Curcuma longa in managing pain in patients suffering from osteoarthritis. Literature was created through various reference sources such as Pubmed, ScienceDirect, Google Scholar, and Epistemonikos which were screened against several inclusion criteria from 2013 - 2023. From the 277 articles obtained, 2 articles were obtained. Curcuma longa has been proven to significantly reduce pain scores according to VAS and WOMAC criteria. Apart from that, its effectiveness is not much different compared to non-steroidal anti-inflammatory drugs (NSAIDs). However, fewer side effects were reported in the Curcuma longa group. Curcuma longa can be used as a therapeutic option for mild to moderate osteoarthritis, especially in patients who cannot tolerate the side effects of NSAIDs.

Title

Found 4 Documents
Search

Abstract

Abstract

Abstract

Abstract

Title Search

Found 4 Documents Search

Abstract

Abstract

Abstract

Abstract

Title

Found 4 Documents
Search